OTLK · Outlook Therapeutics, Inc.
$1.42
+0.04 (+2.90%)
At close · Jul 21
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, there is substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$171.63M
Shares
120.86M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Robert C. Jahr | CEO | $1,291,757 |
| C. Russell Trenary III | CEO | $1,246,752 |
| Jeff Evanson | Chief Commercial Officer | $1,159,107 |
| Lawrence Kenyon | CEO | $476,170 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| C. Russell Trenary III | CEO | $6,377,953 |
| Jeff Evanson | Chief Commercial Officer | $768,029 |
| Lawrence Kenyon | CEO | $634,597 |
| Robert C. Jahr | CEO | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| C. Russell Trenary III | CEO | $1,758,862 |
| Jeff Evanson | Chief Commercial Officer | $718,195 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Terry Dagnon | Chief Operations Officer | $1,433,955 |
| Jeff Evanson | Chief Commercial Officer | $1,408,961 |
| C. Russell Trenary III | CEO | $1,333,179 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| C. Russell Trenary III | CEO | $7,455,612 |
| Lawrence Kenyon | CFO | $2,669,214 |
| Terry Dagnon | Chief Operations Officer | $300,000 |
| Jeff Evanson | Chief Commercial Officer | $300,000 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Lawrence Kenyon | CFO | $1,184,334 |
| Jeff Evanson | Chief Commercial Officer | $159,677 |
| Terry Dagnon | Chief Operations Officer | $159,677 |
| C. Russell Trenary III | CEO | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Lawrence Kenyon | CEO | $1,863,901 |
| Kenneth M. Bahrt | Former Chief Medical Officer | $1,625,250 |
| Terry Dagnon | COO | — |
| Jeff Evanson | Chief Commercial Officer | — |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Lawrence Kenyon | CEO | $716,132 |
| Kenneth M. Bahrt | Former Chief Medical Officer | $429,082 |
| Stephen J. McAndrew | Former Senior Vice President, Business Strategy & Development | $326,071 |
| Terry Dagnon | COO | — |
| Jeff Evanson | Chief Commercial Officer | — |